Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 106 participants.

Also called NCT03195023

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 106 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03195023
Other papers using this trial's data
  • Renin-angiotensin-aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial Hipertension y riesgo vascular, 2024 DOI, PubMed 38508877

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03195023. Randomized; no masking; primary purpose treatment. Start 2015-06 (registry gives no type); primary completion 2019-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)
Acronym
PROERCAN01
Condition
Renal Insufficiency, Chronic
Condition
Proteinuria
Intervention (Drug)
Lisinopril
Intervention (Drug)
Amlodipine
Lead sponsor
Hospital General Universitario Gregorio Marañon (class: other)

Record details

Record id
cardio:ct-nct03195023
Content hash
e867ff4d0389b2d4087ff0d4f09a26c048223c09d95e19d346181c046133cdcc